Febuxostat (sodium)

Febuxostat (sodium)

• CAS Number: 1140907-13-6
• UNSPSC Description: Febuxostat (TEI 6720) sodium is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat sodium has the potential for the research of hyperuricemia and gout[1][2][3].
• Target Antigen: Xanthine Oxidase
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Metabolic Disease; Cardiovascular Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/febuxostat-sodium.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=C(C)N=C(C2=CC=C(OCC(C)C)C(C#N)=C2)S1)O[Na]
• Molecular Weight: 338.36
• References & Citations: [1]Takano Y, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci, 2005, 76(16), 1835-1847.|[2]Sanchez-Lozada LG, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol, 2008, 294(4), F710-F718.|[3]Sanchez-Lozada LG, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol, 2008, 108(4), p69-p78.|[4]Nomura J, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep. 2014 Apr 1;4:4554.|[5]Karve AV, et al. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. Indian J Pharmacol. 2013 May-Jun;45(3):244-7.|[6]Khames A, et al. Ameliorative effects of sildenafil and/or febuxostat on doxorubicin-induced nephrotoxicity in rats. Eur J Pharmacol. 2017 Jun 15;805:118-124.
• Shipping Conditions: Room temperature
• Clinical Information: Launched